97 related articles for article (PubMed ID: 17145574)
1. A phase II trial of miltefosine in patients with cutaneous T-cell lymphoma.
Dumontet C; Thomas L; Bérard F; Gimonet JF; Coiffier B
Bull Cancer; 2006 Nov; 93(11):E115-8. PubMed ID: 17145574
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of topically applied miltefosine solution in patients with skin-metastasized breast cancer.
Terwogt JM; Mandjes IA; Sindermann H; Beijnen JH; ten Bokkel Huinink WW
Br J Cancer; 1999 Mar; 79(7-8):1158-61. PubMed ID: 10098751
[TBL] [Abstract][Full Text] [Related]
3. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.
Mann BS; Johnson JR; Cohen MH; Justice R; Pazdur R
Oncologist; 2007 Oct; 12(10):1247-52. PubMed ID: 17962618
[TBL] [Abstract][Full Text] [Related]
4. Randomized, double-blind, placebo-controlled, multicenter trial of 6% miltefosine solution, a topical chemotherapy in cutaneous metastases from breast cancer.
Leonard R; Hardy J; van Tienhoven G; Houston S; Simmonds P; David M; Mansi J
J Clin Oncol; 2001 Nov; 19(21):4150-9. PubMed ID: 11689583
[TBL] [Abstract][Full Text] [Related]
5. [[Treatment with Miltex for metastatic skin lesions in breast cancer] ].
Moĭseenko VM; Orlova RV; Ermakova NA; Protsenko SA
Vopr Onkol; 2000; 46(5):600-3. PubMed ID: 11202195
[TBL] [Abstract][Full Text] [Related]
6. Loco-regional control of cutaneous metastases of malignant melanoma by treatment with miltefosine (Miltex).
Ragnarsson-Olding B; Djureen-Mårtensson E; Månsson-Brahme E; Hansson J
Acta Oncol; 2005; 44(7):773-7. PubMed ID: 16227173
[No Abstract] [Full Text] [Related]
7. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma.
Whittaker SJ; Demierre MF; Kim EJ; Rook AH; Lerner A; Duvic M; Scarisbrick J; Reddy S; Robak T; Becker JC; Samtsov A; McCulloch W; Kim YH
J Clin Oncol; 2010 Oct; 28(29):4485-91. PubMed ID: 20697094
[TBL] [Abstract][Full Text] [Related]
8. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma.
Duvic M; Martin AG; Kim Y; Olsen E; Wood GS; Crowley CA; Yocum RC;
Arch Dermatol; 2001 May; 137(5):581-93. PubMed ID: 11346336
[TBL] [Abstract][Full Text] [Related]
9. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.
Olsen EA; Kim YH; Kuzel TM; Pacheco TR; Foss FM; Parker S; Frankel SR; Chen C; Ricker JL; Arduino JM; Duvic M
J Clin Oncol; 2007 Jul; 25(21):3109-15. PubMed ID: 17577020
[TBL] [Abstract][Full Text] [Related]
10. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis.
Jha TK; Sundar S; Thakur CP; Bachmann P; Karbwang J; Fischer C; Voss A; Berman J
N Engl J Med; 1999 Dec; 341(24):1795-800. PubMed ID: 10588964
[TBL] [Abstract][Full Text] [Related]
11. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent.
Soto J; Toledo J; Gutierrez P; Nicholls RS; Padilla J; Engel J; Fischer C; Voss A; Berman J
Clin Infect Dis; 2001 Oct; 33(7):E57-61. PubMed ID: 11528586
[TBL] [Abstract][Full Text] [Related]
12. Effects of topical treatment with the raft modulator miltefosine and clobetasol in cutaneous mastocytosis: a randomized, double-blind, placebo-controlled trial.
Hartmann K; Siebenhaar F; Belloni B; Brockow K; Eben R; Hartmann B; Ruëff F; Schoepke N; Staubach P; Weber A; Maurer M
Br J Dermatol; 2010 Jan; 162(1):185-90. PubMed ID: 19785605
[TBL] [Abstract][Full Text] [Related]
13. Comparison of selective retinoic acid receptor- and retinoic X receptor-mediated efficacy, tolerance, and survival in cutaneous t-cell lymphoma.
Querfeld C; Rosen ST; Guitart J; Rademaker A; Fung BB; Posten W; Kuzel TM
J Am Acad Dermatol; 2004 Jul; 51(1):25-32. PubMed ID: 15243520
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma.
Kim YH; Girardi M; Duvic M; Kuzel T; Link BK; Pinter-Brown L; Rook AH
J Am Acad Dermatol; 2010 Dec; 63(6):975-83. PubMed ID: 20888065
[TBL] [Abstract][Full Text] [Related]
15. Diffuse cutaneous leishmaniasis responds to miltefosine but then relapses.
Zerpa O; Ulrich M; Blanco B; Polegre M; Avila A; Matos N; Mendoza I; Pratlong F; Ravel C; Convit J
Br J Dermatol; 2007 Jun; 156(6):1328-35. PubMed ID: 17441955
[TBL] [Abstract][Full Text] [Related]
16. A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis.
Rook AH; Wood GS; Duvic M; Vonderheid EC; Tobia A; Cabana B
J Am Acad Dermatol; 2010 Dec; 63(6):984-90. PubMed ID: 20889234
[TBL] [Abstract][Full Text] [Related]
17. Pegylated doxorubicin for primary cutaneous T cell lymphoma: a report on ten patients with follow-up.
Wollina U; Graefe T; Kaatz M
Ann N Y Acad Sci; 2001 Sep; 941():214-6. PubMed ID: 11594577
[No Abstract] [Full Text] [Related]
18. Six patients with early-stage cutaneous T-cell lymphoma successfully treated with topical 5-fluorouracil.
Kannangara AP; Levitan D; Fleischer AB
J Drugs Dermatol; 2010 Aug; 9(8):1017-8. PubMed ID: 20684155
[TBL] [Abstract][Full Text] [Related]
19. Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma.
Wollina U; Dummer R; Brockmeyer NH; Konrad H; Busch JO; Kaatz M; Knopf B; Koch HJ; Hauschild A
Cancer; 2003 Sep; 98(5):993-1001. PubMed ID: 12942567
[TBL] [Abstract][Full Text] [Related]
20. Malignant melanoma and other second cutaneous malignancies in cutaneous T-cell lymphoma. The influence of additional therapy after total skin electron beam radiation.
Licata AG; Wilson LD; Braverman IM; Feldman AM; Kacinski BM
Arch Dermatol; 1995 Apr; 131(4):432-5. PubMed ID: 7726585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
